IHC | Jotup

GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform

Retrieved on:

Monday, January 8, 2024

Partnership, Health, HER2, IND, Immunohistochemistry, Research, Cancer Moonshot, McKinsey & Company, Cancer, Digital, Laboratory, AI, IHC, Patient, Safety, MFDS, NK

YONGIN, South Korea and SYDNEY, Jan. 8, 2024 /PRNewswire/ -- GC Cell, a fully integrated cell therapy pioneer, is proud to announce the approval from both the Australian Human Research Ethics Committee (HREC) and the Korean Ministry of Food and Drug Safety (MFDS) for a Phase 1 Investigational New Drug (IND) trial for its AB-201 cancer treatment, a HER2 targeted chimeric antigen receptor-natural killer (CAR-NK) cell therapy that shows great promise. Additionally, GC Cell is excited to reveal a strategic partnership with Lunit, the medical AI leader, to enhance precision and clinical intelligence of AB-201's efficacy evaluation by applying its advanced AI technology, in addition to traditional Immunohistochemistry (IHC) based assessments. After participating in the US White House's Cancer Moonshot initiative this past October, both accomplishments represent major milestones in GC Cell's efforts to revolutionize immunotherapy-based cancer treatment while harnessing AI and digital transformation to fight cancer.

Key Points:

After participating in the US White House's Cancer Moonshot initiative this past October, both accomplishments represent major milestones in GC Cell's efforts to revolutionize immunotherapy-based cancer treatment while harnessing AI and digital transformation to fight cancer.
"Our preclinical studies suggest the possibility that AB-201 causes complete cancer remission and tumor suppression," remarked James Park, CEO of GC Cell.
With such quantitative analysis, AI can help standardize the assessment of cancer target expression across different laboratories and geographical locations.
It's a pivotal step in GC Cell's journey towards a digital future, aligning with the broader healthcare industry's shift towards technology-enhanced solutions.

Biocare Medical and Molecular Instruments Partner to Revolutionize Automated Bioimaging Through ONCORE Pro X and HCR™ RNA-ISH Assays

Retrieved on:

Friday, January 5, 2024

RNA, In situ hybridization, Partnership, Drug development, Imaging, Research, SAN, ISH, Temperature, IHC, Immunohistochemistry, Paradigm

Molecular Instruments®: Inventor of the HCR™ Platform: Molecular Instruments®, the market disruptor in bioimaging and ISH reagents, brings to the table their patented HCR™ Imaging technology.

Key Points:

Molecular Instruments®: Inventor of the HCR™ Platform: Molecular Instruments®, the market disruptor in bioimaging and ISH reagents, brings to the table their patented HCR™ Imaging technology.
Biocare Medical's ONCORE Pro X: A Paradigm in Automation: Recognized as a leader in automated instrumentation, Biocare Medical's ONCORE Pro X exemplifies innovation and versatility.
Synergizing Strengths for Advanced Bioimaging: The integration of MI's HCR™ Platform into Biocare Medical's ONCORE Pro X instrument represents a synergy of strengths.
A New Era in Bioimaging: By integrating Biocare Medical's advanced automated instrumentation with the revolutionary HCR™ Platform from Molecular Instruments, researchers can now harness the power of the ONCORE Pro.

DeciBio Forecasts the Global Clinical Oncology Biomarker Testing Market to Grow at 13% p.a., Reaching ~$12.6B in 2028 - Market Report by DeciBio Consulting LLC

Retrieved on:

Wednesday, January 3, 2024

DeciBio Consulting LLC’s latest market report, “Global Clinical Oncology Biomarker Testing Market Report, Second Edition: 2023-2028,” states that the global clinical oncology biomarker testing market is predicted to reach $12.6B by 2028, driven by increased access to precision medicine therapeutics.

Key Points:

DeciBio Consulting LLC’s latest market report, “Global Clinical Oncology Biomarker Testing Market Report, Second Edition: 2023-2028,” states that the global clinical oncology biomarker testing market is predicted to reach $12.6B by 2028, driven by increased access to precision medicine therapeutics.
The second edition of DeciBio’s Clinical Oncology Biomarker Testing Report takes a comprehensive look at biomarker testing for patient stratification, therapy selection, and prognosis for cancer treatment globally, including both products (kits) and services.
NGS, PCR, and IHC are the primary technologies utilized for clinical biomarker testing today.
Increased access to each of these technologies, as well as to the precision medicines requiring testing, is expected to drive significant growth of the biomarker testing market in the near-mid term.

PureHealth shares settled a staggering 76% above listing price in Abu Dhabi trading debut

Retrieved on:

Thursday, December 21, 2023

Science, Health, PJSC, AED, ADX, Competitiveness Council, IHC, Security, Economic development, Longevity, Growth, IPO, First Abu Dhabi Bank, ADQ, Offering, Abu Dhabi Securities Exchange

Abu Dhabi-based PureHealth, which is trading under the symbol "PureHealth", witnessed a jump in its share price to AED 6.0 per share in early trading on the ADX on Wednesday 20 December, giving it a market value of AED 66.6 billion.

Key Points:

Abu Dhabi-based PureHealth, which is trading under the symbol "PureHealth", witnessed a jump in its share price to AED 6.0 per share in early trading on the ADX on Wednesday 20 December, giving it a market value of AED 66.6 billion.
Shares of the company surged to a high of 84% before they settled around 76% above the listing price at AED 5.74 per share at the close of trading on Wednesday (indicating a market value of AED 63.8 billion).
Farhan Malik, Founder and Managing Director of PureHealth rang the ADX market opening bell to celebrate the listing, in the presence of H.E.
Ahmed Jasim Al Zaabi, Chairman of Abu Dhabi Department of Economic Development, H.E Syed Basar Shueb, CEO and Managing Director of International Holding Company, H.E.

PureHealth shares settled a staggering 76% above listing price in Abu Dhabi trading debut

Retrieved on:

Thursday, December 21, 2023

Science, Health, PJSC, AED, ADX, Competitiveness Council, IHC, Security, Economic development, Longevity, Growth, IPO, First Abu Dhabi Bank, ADQ, Offering, Abu Dhabi Securities Exchange

Abu Dhabi-based PureHealth, which is trading under the symbol "PureHealth", witnessed a jump in its share price to AED 6.0 per share in early trading on the ADX on Wednesday 20 December, giving it a market value of AED 66.6 billion.

Key Points:

Abu Dhabi-based PureHealth, which is trading under the symbol "PureHealth", witnessed a jump in its share price to AED 6.0 per share in early trading on the ADX on Wednesday 20 December, giving it a market value of AED 66.6 billion.
Shares of the company surged to a high of 84% before they settled around 76% above the listing price at AED 5.74 per share at the close of trading on Wednesday (indicating a market value of AED 63.8 billion).
Farhan Malik, Founder and Managing Director of PureHealth rang the ADX market opening bell to celebrate the listing, in the presence of H.E.
Ahmed Jasim Al Zaabi, Chairman of Abu Dhabi Department of Economic Development, H.E Syed Basar Shueb, CEO and Managing Director of International Holding Company, H.E.

Marriott Vacations Worldwide Appoints Mary E. Galligan to Board of Directors

Retrieved on:

Monday, December 11, 2023

Marriott Vacations Worldwide Corporation (NYSE: VAC) (“MVW” or the “Company”) announced today the appointment of Mary E. Galligan to its Board of Directors effective January 1, 2024.

Key Points:

Marriott Vacations Worldwide Corporation (NYSE: VAC) (“MVW” or the “Company”) announced today the appointment of Mary E. Galligan to its Board of Directors effective January 1, 2024.
Ms. Galligan joins the MVW Board following a 35-year career in technology and cybersecurity, government relations and risk management.
View the full release here: https://www.businesswire.com/news/home/20231211409126/en/
Marriott Vacations Worldwide Corporation has appointed Mary E. Galligan to its Board of Directors.
"Ms. Galligan brings critical knowledge to our Board of Directors, having an impressive career in technology and cybersecurity.

Integrative Life Network and Integrative Health Centers Merge to Redefine the Patient Journey for Mental and Behavioral Health

Retrieved on:

Thursday, November 30, 2023

Integrative Life Network, LLC (ILN) and Integrative Health Centers, Inc. (IHC) announced today that they have merged to create a new, unified mental and behavioral healthcare company called Peregrine Health, Inc. (Peregrine).

Key Points:

Integrative Life Network, LLC (ILN) and Integrative Health Centers, Inc. (IHC) announced today that they have merged to create a new, unified mental and behavioral healthcare company called Peregrine Health, Inc. (Peregrine).
View the full release here: https://www.businesswire.com/news/home/20231130898505/en/
ILN is a network of residential, partial-hospitalization, and intensive outpatient programs in four states providing high-acuity treatment options for a range of mental and behavioral health disorders.
IHC is a nationwide telemedicine platform that connects clinics, hospitals, and health systems in underserved communities with specialized mental and behavioral health providers.
“Very few providers have successfully integrated the diagnosis, innovative treatment, and ongoing care of mental and behavioral health disorders into their delivery models.

Biocare Medical Unveils intelliPATH+: Next-Generation Enhancement of the Proven intelliPATH FLX Staining System

Retrieved on:

Tuesday, December 5, 2023

In situ hybridization, Immunohistochemistry, Workflow, Research, SAN, ISH, IVD, Temperature, ARC, IHC

SAN FRANCISCO, Dec. 5, 2023 /PRNewswire/ -- Biocare Medical, a leader in immunohistochemistry (IHC) and in situ hybridization (ISH) diagnostics, is proud to introduce the intelliPATH+ Advanced Staining Instrument.

Key Points:

SAN FRANCISCO, Dec. 5, 2023 /PRNewswire/ -- Biocare Medical, a leader in immunohistochemistry (IHC) and in situ hybridization (ISH) diagnostics, is proud to introduce the intelliPATH+ Advanced Staining Instrument.
The intelliPATH+ has been meticulously redesigned with input from users and the latest technological advancements to become a fully open system that accommodates continuous random access with immediate STAT capabilities.
It offers a seamless workflow with increased speed and superior quality in IHC staining, all while reducing waste.
The intelliPATH+ system takes command of every analytical detail in the staining process.

PureHealth, Region's Largest Healthcare Platform Announces Intention to List on the ADX

Retrieved on:

Monday, November 20, 2023

Pura, Health, Longevity, Acquisition, Abu Dhabi Securities Exchange, ADQ, Patient, Science, Pharmacy, IPO, Ardent Health Services, Growth, Health care, Hospital, Joint-stock company, ADX, IHC, Digital health, Amusement park

Subject to obtaining regulatory approvals and other relevant considerations it is expected that trading on ADX will commence in December 2023.

Key Points:

Subject to obtaining regulatory approvals and other relevant considerations it is expected that trading on ADX will commence in December 2023.
PureHealth is committed to raising standards in healthcare excellence, facilitating the development of cutting-edge healthcare solutions, and advancing the science of longevity.
PureHealth works towards its stated purpose of remaining at the forefront of advancing health systems and envisioning the healthcare of the future.
Hamad Al Hammadi, Chairman of the Board of Directors of PureHealth, said: "Healthcare is a fundamental pillar of any thriving society.

Biocare Medical Announces the Launch of ARC: The New IVD Antigen Retrieval Chamber for Reliable, Precise and Consistent Heat Induced Epitope Retrieval (HIER)

Retrieved on:

Wednesday, November 15, 2023

Pressure, Immunohistochemistry, Research, SAN, Tissue, ISH, Antigen retrieval, Laboratory, In situ hybridization, ARC, Temperature, IVD, IHC

SAN FRANCISCO, Nov. 15, 2023 /PRNewswire/ -- Biocare Medical, a leading provider in the immunohistochemistry sector, introduces their newest innovation: ARC (Antigen Retrieval Chamber).

Key Points:

SAN FRANCISCO, Nov. 15, 2023 /PRNewswire/ -- Biocare Medical, a leading provider in the immunohistochemistry sector, introduces their newest innovation: ARC (Antigen Retrieval Chamber).
The addition of ARC to their automation portfolio advances Biocare Medical's suite of decloaking systems built for consistent, reliable heat-induced epitope retrieval.
Tailored for Heat-Induced Epitope Retrieval (HIER) with in vitro diagnostic (IVD) labeling, ARC delivers precision and consistency.
Recognizing the need for accurate heat, pressure, and buffer solutions, ARC is vital for reliable immunohistochemistry (IHC) and in situ hybridization (ISH) staining.